Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel Phase 3 Trial in Japan
jRCT1080224553Phase 3Terminated
- Start
- Feb 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 3 trial of tisagenlecleucel in cancer. Started Feb 2019; status: terminated.
02
Drugs
tisagenlecleucel
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT1080224553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224553.